Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms

Rheumatology

Volumn 49, Issue 3, 2009, Pages 458-466

  Balsa, Alejandro ^a   del Amo, Jokin ^b   Blanco, Francisco ^c   Caliz, Rafael ^d   Silva, Lucía ^e   Sanmarti, Raimon ^f   Martínez, Francisco G ^g   Tejedor, Diego ^b   Artieda, Marta ^b   Pascual Salcedo, Dora ^a   Oreiro, Natividad ^c   Collado, Maria D ^d   Andreu, Jose L ^e   Graell, Eduard ^f   Simón, Laureano ^b   Martínez, Antonio ^b   Mulero, Juan ^e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Research and Development Department   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Genetic markers; Prognosis; Rheumatoid arthritis; SNPs

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DR ANTIGEN; INTERLEUKIN 4; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RHEUMATOID FACTOR;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BONE RADIOGRAPHY; CIGARETTE SMOKING; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE DURATION; DISEASE MODEL; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL DISEASE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NEPHELOMETRY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISABILITY EVALUATION; EPIDEMIOLOGIC METHODS; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; INTERLEUKIN-4; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES, CYCLIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REMISSION INDUCTION;

EID: 77950525477     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep380     Document Type: Article

References (58)

1. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19:137-46.
2. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23 (5 Suppl. 39),S43-52.
3. Saleem B, Nizam S, Emery P. Can remission be main-tained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006;24(6 Suppl. 43),S33-6.
4. Pincus T, Kavanaugh A, Aletaha D, Smolen J. Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006;24(6 Suppl. 43),S1-6.
5. Landewe R. Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 2007;80:8-15.
6. Brennan P, Harrison B, Barrett E et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. Br Med J 1996;313:471-6.
7. Scott DL. The diagnosis and prognosis of early rheuma-toid arthritis: rationales for new prognostic criteria. Arthritis Rheum 2002;46:286-90.
8. Berglin E, Johansson T, Sundin U et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
9. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008;10: 205.
10. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480-8.
11. Tejedor D, Castillo S, Mozas P et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005;51:1137-44.
12. Michou L, Croiseau P, Petit-Teixeira E et al. Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid arthritis. Arthritis Res Ther 2006;8:R79.
13. Harrel FE. Regression modeling strategies. New York: Springer, 2001.
14. . R-Development Core Team. (2008) A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
15. Akkad DA, Arning L, Ibrahim SM, Epplen JT. Sex specifically associated promoter polymorphism in multiple sclerosis affects interleukin 4 expression levels. Genes Immun 2007;8:703-6.
16. Nunez C, Santiago JL, Varade J et al. IL4 in the 5q31 context: association studies of type 1 diabetes and rheumatoid arthritis in the Spanish population. Immunogenetics 2008;60:19-23.
17. Orozco G, Sanchez E, Gonzalez-Gay MA et al. Association of a functional single-nucleotide polymorph-ism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005;52:219-24.
18. Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J Rheumatol 2008;35:995-1001.
19. e Vries-Bouwstra J, le CS, Allaart C, Breedveld F, Huizinga T. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. J Rheumatol 2006 33:1747-53.
20. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9-44.
21. Pincus T. Rheumatology function tests: quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases. Clin Exp Rheumatol 2005;23(5 Suppl. 39),S85-9.
22. Bruce B, Fries JF. The health assessment questionnaire (HAQ). Clin Exp Rheumatol 2005;23(5 Suppl 39),S14-8.
23. Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003;21(Suppl. 31),S20-7.
24. Aletaha D, Strand.V, Smolen JS, Ward MM. Treatmentrelated improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
25. Drossaers-Bakker KW, de BM, van ZD, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.
26. Welsing PM, Landewe RB, van Riel PL et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
27. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
28. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35.
29. Meyer O, Labarre C, Dougados M et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
30. Nielen MM, van der Horst AR, van SD et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005;64: 1199-204.
31. Syversen SW, Gaarder PI, Goll GL et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-7.
32. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
33. Kuhn KA, Kulik L, Tomooka B et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116:961-73.
34. Mikuls TR, O'Dell JR, Stoner JA et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-82.
35. de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: to be or not to be anti-CCP positive. J Autoimmun 2005;25(Suppl),21-5.
36. Klareskog L, Padyukov L, Ronnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006;18:650-5.
37. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006;65:366-71.
38. van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007;56:425-32.
39. Albanesi C, Fairchild HR, Madonna S et al. IL-4 and IL-13 negatively regulate TNF-alphaand IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007;179:984-92.
40. Vallance BA, Radojevic N, Hogaboam CM, Deng Y, Gauldie J, Collins SM. IL-4 gene transfer to the small bowel serosa leads to intestinal inflammation and smooth muscle hyperresponsiveness. Am J Physiol Gastrointest Liver Physiol 2007;292:G385-94.
41. Ho SH, Hahn W, Lee HJ et al. Protection against collageninduced arthritis by electrotransfer of an expression plasmid for the interleukin-4. Biochem Biophys Res Commun 2004;321:759-66.
42. Klein W, Tromm A, Griga T et al. Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases. Genes Immun 2001;2:287-9.
43. Nakashima H, Miyake K, Inoue Y et al. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 2002;3:107-9.
44. Moreno O, Gonzalez CI, Saaibi DL et al. Polymorphisms in the IL4 and IL4RA genes in Colombian patients with rheumatoid arthritis. J Rheumatol 2007;34:36-42.
45. Pertovaara M, Antonen J, Hurme M. Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome. Ann Rheum Dis 2006;65:666-70.
46. Pawlik A, Wrzesniewska J, Florczak M, GawronskaSzklarz B, Herczynska M. The -590 IL-4 promoter polymorphism in patients with rheumatoid arthritis. Rheumatol Int 2005;26:48-51.
47. Genevay S, di Giovine FS, Perneger TV et al. Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum 2002;47:303-9.
48. Brown AK, Quinn MA, Karim Z et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54: 3761-73.
49. Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
50. van der Helm-van Mil AH, Breedveld FC, Huizinga TW. Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 2006;8:216.
51. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
52. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther 2005;8:R19.
53. Orozco G, Pascual-Salcedo D, Lopez-Nevot MA et al. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology 2008;47: 138-41.
54. Kallberg H, Padyukov L, Plenge RM et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-75.
55. Wesoly J, van der Helm-van Mil AH, Toes RE et al. Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum 2005;52:2948-50.
56. Liu H, Li J, Wong L. Use of extreme patient samples for outcome prediction from gene expression data. Bioinformatics 2005;21:3377-84.
57. Naseem H, Thomson W, Silman A, Worthington J, Symmons D, Barton A. The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome. Ann Rheum Dis 2008;67:251-5.
58. Lie BA, Viken MK, Odegard S et al. Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2007;66:1604-9.